当前位置: X-MOL 学术Adv. Anat. Pathol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.
Advances in Anatomic Pathology ( IF 6.7 ) Pub Date : 2017-8-5 , DOI: 10.1097/pap.0000000000000162
Shona Hendry 1 , Roberto Salgado , Thomas Gevaert , Prudence A Russell , Tom John , Bibhusal Thapa , Michael Christie , Koen van de Vijver , M V Estrada , Paula I Gonzalez-Ericsson , Melinda Sanders , Benjamin Solomon , Cinzia Solinas , Gert G G M Van den Eynden , Yves Allory , Matthias Preusser , Johannes Hainfellner , Giancarlo Pruneri , Andrea Vingiani , Sandra Demaria , Fraser Symmans , Paolo Nuciforo , Laura Comerma , E A Thompson , Sunil Lakhani , Seong-Rim Kim , Stuart Schnitt , Cecile Colpaert , Christos Sotiriou , Stefan J Scherer , Michail Ignatiadis , Sunil Badve , Robert H Pierce , Giuseppe Viale , Nicolas Sirtaine , Frederique Penault-Llorca , Tomohagu Sugie , Susan Fineberg , Soonmyung Paik , Ashok Srinivasan , Andrea Richardson , Yihong Wang , Ewa Chmielik , Jane Brock , Douglas B Johnson , Justin Balko , Stephan Wienert , Veerle Bossuyt , Stefan Michiels , Nils Ternes , Nicole Burchardi , Stephen J Luen , Peter Savas , Frederick Klauschen , Peter H Watson , Brad H Nelson , Carmen Criscitiello , Sandra O'Toole , Denis Larsimont , Roland de Wind , Giuseppe Curigliano , Fabrice André , Magali Lacroix-Triki , Mark van de Vijver , Federico Rojo , Giuseppe Floris , Shahinaz Bedri , Joseph Sparano , David Rimm , Torsten Nielsen , Zuzana Kos , Stephen Hewitt , Baljit Singh , Gelareh Farshid , Sibylle Loibl , Kimberly H Allison , Nadine Tung , Sylvia Adams , Karen Willard-Gallo , Hugo M Horlings , Leena Gandhi , Andre Moreira , Fred Hirsch , Maria V Dieci , Maria Urbanowicz , Iva Brcic , Konstanty Korski , Fabien Gaire , Hartmut Koeppen , Amy Lo , Jennifer Giltnane , Marlon C Rebelatto , Keith E Steele , Jiping Zha , Kenneth Emancipator , Jonathan W Juco , Carsten Denkert , Jorge Reis-Filho , Sherene Loi , Stephen B Fox
Affiliation  

Assessment of tumor-infiltrating lymphocytes (TILs) in histopathologic specimens can provide important prognostic information in diverse solid tumor types, and may also be of value in predicting response to treatments. However, implementation as a routine clinical biomarker has not yet been achieved. As successful use of immune checkpoint inhibitors and other forms of immunotherapy become a clinical reality, the need for widely applicable, accessible, and reliable immunooncology biomarkers is clear. In part 1 of this review we briefly discuss the host immune response to tumors and different approaches to TIL assessment. We propose a standardized methodology to assess TILs in solid tumors on hematoxylin and eosin sections, in both primary and metastatic settings, based on the International Immuno-Oncology Biomarker Working Group guidelines for TIL assessment in invasive breast carcinoma. A review of the literature regarding the value of TIL assessment in different solid tumor types follows in part 2. The method we propose is reproducible, affordable, easily applied, and has demonstrated prognostic and predictive significance in invasive breast carcinoma. This standardized methodology may be used as a reference against which other methods are compared, and should be evaluated for clinical validity and utility. Standardization of TIL assessment will help to improve consistency and reproducibility in this field, enrich both the quality and quantity of comparable evidence, and help to thoroughly evaluate the utility of TILs assessment in this era of immunotherapy.

中文翻译:

评估实体瘤中的肿瘤浸润淋巴细胞:国际免疫肿瘤学生物标志物工作组对病理学家的实践审查和标准化方法的建议:第 1 部分:评估宿主免疫反应、原位浸润性乳腺癌和导管癌、转移性肿瘤中的 TIL存款和进一步研究的领域。

评估组织病理学标本中的肿瘤浸润淋巴细胞 (TIL) 可以为多种实体瘤类型提供重要的预后信息,也可能对预测治疗反应有价值。然而,尚未实现作为常规临床生物标志物的实施。随着免疫检查点抑制剂和其他形式的免疫疗法的成功使用成为临床现实,对广泛适用、可获得且可靠的免疫肿瘤学生物标志物的需求显而易见。在本综述的第 1 部分中,我们简要讨论了宿主对肿瘤的免疫反应和 TIL 评估的不同方法。我们提出了一种标准化的方法来评估原发性和转移性环境中苏木精和伊红切片实体瘤中的 TIL,基于浸润性乳腺癌 TIL 评估的国际免疫肿瘤学生物标志物工作组指南。第 2 部分对有关 TIL 评估在不同实体瘤类型中的价值的文献进行了回顾。我们提出的方法可重复、负担得起、易于应用,并且已证明对浸润性乳腺癌的预后和预测意义。这种标准化方法可用作与其他方法进行比较的参考,并且应对临床有效性和实用性进行评估。TIL评估的标准化将有助于提高该领域的一致性和可重复性,丰富可比证据的质量和数量,并有助于全面评估TILs评估在免疫治疗时代的效用。第 2 部分对有关 TIL 评估在不同实体瘤类型中的价值的文献进行了回顾。我们提出的方法可重复、负担得起、易于应用,并且已证明对浸润性乳腺癌的预后和预测意义。这种标准化方法可用作与其他方法进行比较的参考,并且应对临床有效性和实用性进行评估。TIL评估的标准化将有助于提高该领域的一致性和可重复性,丰富可比证据的质量和数量,并有助于全面评估TILs评估在免疫治疗时代的效用。第 2 部分对有关 TIL 评估在不同实体瘤类型中的价值的文献进行了回顾。我们提出的方法可重复、负担得起、易于应用,并且已证明对浸润性乳腺癌的预后和预测意义。这种标准化方法可用作与其他方法进行比较的参考,并且应对临床有效性和实用性进行评估。TIL评估的标准化将有助于提高该领域的一致性和可重复性,丰富可比证据的质量和数量,并有助于全面评估TILs评估在免疫治疗时代的效用。并已证明在浸润性乳腺癌中具有预后和预测意义。这种标准化方法可用作与其他方法进行比较的参考,并且应对临床有效性和实用性进行评估。TIL评估的标准化将有助于提高该领域的一致性和可重复性,丰富可比证据的质量和数量,并有助于全面评估TILs评估在免疫治疗时代的效用。并已证明在浸润性乳腺癌中具有预后和预测意义。这种标准化方法可用作与其他方法进行比较的参考,并且应对临床有效性和实用性进行评估。TIL评估的标准化将有助于提高该领域的一致性和可重复性,丰富可比证据的质量和数量,并有助于全面评估TILs评估在免疫治疗时代的效用。
更新日期:2017-08-05
down
wechat
bug